We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
76
DELISTED
Adamas Pharmaceuticals
ADMS
$4.13M 0.04%
172,630
– –
CRBP icon
77
Corbus Pharmaceuticals
CRBP
$201M
$4.03M 0.03%
22,024
– –
CMTA
78
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.79M 0.03%
250,000
– –
LUMO
79
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.68M 0.03%
56,364
-55,555
-50% -$3.94M
TRIL
80
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.95M 0.03%
409,323
– –
TTPH
81
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.87M 0.02%
46,750
– –
ARAV
82
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.35M 0.02%
237,718
– –
JNCE
83
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.23M 0.02%
100,000
– –
NTRA icon
84
Natera
NTRA
$47.9B
$2.12M 0.02%
228,676
– –
TNXP icon
85
Tonix Pharmaceuticals
TNXP
$215M
– –
0
– –
KRYS icon
86
Krystal Biotech
KRYS
$10.3B
$2.02M 0.02%
200,000
– –
OVID icon
87
Ovid Therapeutics
OVID
$547M
$1.75M 0.01%
247,733
-85,600
-26% -$693K
CLLS
88
Cellectis
CLLS
$342M
$1.58M 0.01%
50,000
– –
TRVN
89
DELISTED
Trevena, Inc.
TRVN
$1.56M 0.01%
1,520
– –
VIRX
90
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.51M 0.01%
15,905
-5,285
-25% -$906K
DVAX
91
DELISTED
Dynavax Technologies
DVAX
$1.49M 0.01%
75,000
– –
INFI
92
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.22M 0.01%
580,400
– –
MDWD icon
93
MediWound
MDWD
$171M
$1.18M 0.01%
32,286
– –
ADAP
94
DELISTED
Adaptimmune Therapeutics
ADAP
$1.12M 0.01%
100,000
– –
RNAC icon
95
Cartesian Therapeutics
RNAC
$304M
$955K 0.01%
3,125
-6,332
-67% -$1.8M
RARX
96
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$945K 0.01%
177,952
– –
ABUS icon
97
Arbutus Biopharma
ABUS
$1.03B
$903K 0.01%
180,582
– –
AIXC
98
AIxCrypto Holdings Inc
AIXC
$22.7M
$762K 0.01%
22
– –
TARA icon
99
Protara Therapeutics
TARA
$228M
$746K 0.01%
7,465
– –
AFMD
100
DELISTED
Affimed
AFMD
$740K 0.01%
40,000
– –
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2018 Portfolio in Review

As of Q1 2018, Julian Baker held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Julian Baker deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was Yarrow Bioscience: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Julian Baker's largest Q1 2018 buy was Yarrow Bioscience: 194 shares worth $26.3M.
  • Julian Baker added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Julian Baker's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Julian Baker fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Julian Baker's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Julian Baker opened 5 new positions and closed 13 in Q1 2018.
  • Julian Baker's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.